Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay

Journal of Molecular Diagnostics

Volumn 13, Issue 2, 2011, Pages 180-188

  Kristensen, Thomas ^a   Vestergaard, Hanne ^a   Møller, Michael Boe ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; STEM CELL FACTOR;

ADULT; AGED; ALLELE; ARTICLE; BONE MARROW BIOPSY; BONE MARROW CELL; CELL FRACTIONATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; FLOW CYTOMETRY; HUMAN; MALE; MAST CELL; PROGNOSIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RELIABILITY; SENSITIVITY ANALYSIS; SKIN BIOPSY; SYSTEMIC MASTOCYTOSIS;

EID: 79952270487     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmoldx.2010.10.004     Document Type: Article

References (33)

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (Eds.): WHO classification of tumours of haematopoietic and lymphoid tissues. IARC: Lyon 2008, 54-63
2. Metcalfe DD: Mast cells and mastocytosis. Blood 2008, 112:946-956
3. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, Sanchez ML, Nunez R, Prados A, Aldanondo I, Sanchez L, Dominguez M, Botana LM, Sanchez-Jimenez F, Sotlar K, Almeida J, Escribano L, Orfao A: KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006, 108:2366-2372 (Pubitemid 44497521)
4. Escribano L, Alvarez-Twose I, Sanchez-Munoz L, Garcia-Montero A, Nunez R, Almeida J, Jara-Acevedo M, Teodosio C, Garcia-Cosio M, Bellas C, Orfao A: Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allerg Clin Immunol 2009, 124:514-521
5. Orfao A, Garcia-Montero AC, Sanchez L, Escribano L: Recent advances in the understanding of mastocytosis: the role of KIT mutations. Br J Haematol 2007, 138:12-30 (Pubitemid 46889785)
6. Ferrao PT, Gonda TJ, Ashman LK: Constitutively active mutant D816VKit induces megakayocyte and mast cell differentiation of early haemopoietic cells from murine foetal liver. Leuk Res 2003, 27:547-555 (Pubitemid 36315787)
7. Zappulla JP, Dubreuil P, Desbois S, Letard S, Ben Hamouda N, Daeron M, Delsol G, Arock M, Liblau RS: Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation. J Exp Med 2005, 202:1635-1641 (Pubitemid 41815869)
8. Mayerhofer M, Gleixner KV, Hoelbl A, Florian S, Hoermann G, Aichberger KJ, Bilban M, Esterbauer H, Krauth MT, Sperr WR, Longley JB, Kralovics R, Moriggl R, Zappulla J, Liblau RS, Schwarzinger I, Sexl V, Sillaber C, Valent P: Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens. J Immunol 2008, 180:5466-5476
9. Valent P, Akin C, Escribano L, Fodinger M, Hartmann K, Brockow K, Castells M, Sperr WR, Kluin-Nelemans HC, Hamdy NAT, Lortholary O, Robyn J, van Doormaal J, Sotlar K, Hauswirth AW, Arock M, Hermine O, Hellmann A, Triggiani M, Niedoszytko M, Schwartz LB, Orfao A, Horny HP, Metcalfe DD: Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007, 37:435-453 (Pubitemid 46817344)
10. Pardanani A, Tefferi A: Systemic mastocytosis in adults: a review on prognosis and treatment based on 342 Mayo Clinic patients and current literature. Curr Opin Hematol 2010, 17:125-132
11. Akin C, Fumo G, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD: A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2004, 103:3222-3225 (Pubitemid 38451702)
12. Zermati Y, De Sepulveda P, Feger F, Letard S, Kersual J, Casteran N, Gorochov G, Dy M, Dumas AR, Dorgham K, Parizot C, Bieche Y, Vidaud M, Lortholary O, Arock M, Hermine O, Dubreuil P: Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene 2003, 22:660-664 (Pubitemid 36269279)
13. Lim KH, Tefferi A, Lasho TL, Finke C, Patnaik M, Butterfield JH, McClure RF, Li CY, Pardanani A: Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood 2009, 113:5727-5736
14. Pardanani A, Tefferi A: A critical reappraisal of treatment response criteria in systemic mastocytosis and a proposal for revisions. Eur J Haematol 2010, 84:371-378
15. Escribano L, Diaz-Agustin B, Lopez A, Lopez RN, Garcia-Montero A, Almeida J, Prados A, Angulo M, Herrero S, Orfao A: Immunophenotypic analysis of mast cells in mastocytosis: when and how to do it. Proposals of the Spanish network on mastocytosis (REMA) Cytom Part B Clin Cytom 2004, 58B:1-8 (Pubitemid 38332714)
16. Roederer M: Spectral compensation for flow cytometry: visualization artifacts, limitations, and caveats. Cytometry 2001, 45:194-205
17. Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001, 29:e45
18. Gabert J, Beillard E, van der Velden VHJ, Bi W, Grimwade D, Pallisgaard N, Barbany G, Cazzaniga G, Cayuela JM, Cave H, Pane F, Aerts JLE, De Micheli D, Thirion X, Pradel V, Gonzalez M, Viehmann S, Malec M, Saglio G, van Dongen JJM: Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer Program. Leukemia 2003, 17:2318-2357
19. van der Velden VH, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, van Dongen JJ: Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 2003, 17:1013-1034 (Pubitemid 36722231)
20. Zhao W, Bueso-Ramos CE, Verstovsek S, Barkoh BA, Khitamy AA, Jones D: Quantitative profiling of codon 816 KIT mutations can aid in the classification of systemic mast cell disease. Leukemia 2007, 21:1574-1576 (Pubitemid 46965305)
21. Fritsche-Polanz R, Jordan JH, Feix A, Sperr WR, Sunder-Plassmann G, Valent P, Fodinger M: Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br J Haematol 2001, 113:357-364 (Pubitemid 32523138)
22. Sotlar K, Escribano L, Landt F, Mohrle S, Herrero S, Torrelo A, Lass U, Horny HP, Bultmann B: One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. Am J Pathol 2003, 162:737-746 (Pubitemid 36237482)
23. Tan A, Westerman D, McArthur GA, Lynch K, Waring P, Dobrovic A: Sensitive detection of KIT D816V in patients with mastocytosis. Clin Chem 2006, 52:2250-2257 (Pubitemid 44924999)
24. Schumacher JA, Elenitoba-Johnson KSJ, Lim MS: Detection of the c-kit D816V mutation in systemic mastocytosis by allele-specific PCR. J Clin Pathol 2008, 61:109-114 (Pubitemid 351158235)
25. Kahler C, Didlaukat S, Feller AC, Merz H: Sensitive and reliable detection of Kit point mutation Asp 816 to Val in pathological material. Diagn Pathol 2007, 2:37
26. Steensma DP: JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility - a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn 2006, 8:397-411
27. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaecla J, Baccarani M, Cortes J, Cross NCP, Druker BJ, Gabert J, Grimwade D, Hehlmann R, Kamel-Reid S, Lipton JH, Longtine J, Martinelli G, Saglio G, Soverini S, Stock W, Goldman JM: Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006, 108:28-37 (Pubitemid 43990609)
28. Corless CL, Harrell P, Lacouture M, Bainbridge T, Le C, Gatter K, White C, Granter S, Heinrich MC: Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukemia. J Mol Diagn 2006, 8:604-612 (Pubitemid 44774160)
29. Valentini CG, Rondoni M, Pogliani EM, Van Lint MT, Cattaneo C, Marbello L, Pulsoni A, Giona F, Martinelli G, Leone G, Pagano L: Mast cell leukemia: a report of ten cases. Ann Hematol 2008, 87:505-508
30. Pagano L, Valentini CG, Caira M, Rondoni M, Van Lint MT, Candoni A, Allione B, Cattaneo C, Marbello L, Caramatti C, Pogliani EM, Iannitto E, Giona F, Ferrara F, Invernizzi R, Fanci R, Lunghi M, Fianchi L, Sanpaolo G, Stefani PM, Pulsoni A, Martinelli G, Leone G, Musto P: Advanced mast cell disease: an Italian Hematological Multicenter experience. Int J Hematol 2008, 88:483-488
31. Sotlar K, Colak S, Bache A, Berezowska S, Krokowski M, Bultmann B, Valent P, Horny HP: Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD). J Pathol 2010, 220:586-595
32. Taylor ML, Sehgal D, Raffeld M, Obiakor H, Akin C, Mage RG, Metcalfe DD: Demonstration that mast cells. T cells, and B cells bearing the activating kit mutation D816V occur in clusters within the marrow of patients with mastocytosis. J Mol Diagn 2004, 6:335-342 (Pubitemid 39517401)
33. Worobec AS, Semere T, Nagata H, Metcalfe DD: Clinical correlates of the presence of the Asp816Val c-kit mutation in the peripheral blood mononuclear cells of patients with mastocytosis. Cancer 1998, 83: 2120-2129 (Pubitemid 28525393)